RevMedx wins $11.4 million Pentagon award to expand XSTAT production

RevMedx was selected for an $11.4 million APFIT award sponsored by the Defense Health Agency to scale U.S. production of its XSTAT hemorrhage control devices for military use. The funding is meant to move the FDA-cleared P15 and P30 from limited fielding to broader procurement across the services.

Why it matters: - Uncontrolled bleeding remains the leading preventable cause of death on the battlefield. - The APFIT award is meant to help a proven trauma device reach broader use across the U.S. military. - The funding also supports domestic manufacturing capacity for combat casualty care.

What happened: - RevMedx was selected for an $11.4 million award through the Department of War’s Accelerate the Procurement and Fielding of Innovative Technologies program. - The award is sponsored by the Defense Health Agency. - The funding will support expanded domestic production of the XSTAT P15 and XSTAT P30. - The devices are intended for fielding across the U.S. military services.

The details: - XSTAT is a handheld applicator that injects compressed minisponges into a wound. - The minisponges expand within seconds to apply internal pressure and stop bleeding without sustained manual compression. - The platform was developed starting in 2008 at the request of U.S. Special Operations Command. - The FDA cleared XSTAT in 2014 through the de novo pathway. - Special Operations Forces began fielding XSTAT in 2015. - The device has been incorporated into Tactical Combat Casualty Care doctrine. - In November 2025, XSTAT P15 received FDA 510(k) clearance through a joint development effort with the Naval Advanced Medical Development office of Naval Medical Research Command. - RevMedx says the APFIT award will support manufacturing expansion, strengthen the domestic industrial base for combat casualty care, and sustain skilled manufacturing jobs at the company and among U.S. contract manufacturing partners. - XSTAT P30 and XSTAT P15 are available by prescription only. - Federal law restricts sale of these devices to or on the order of a physician. - More information is available at revmedx.com. - Additional details on the FY 2026 APFIT awards are available on war.gov/news.

Between the lines: - XSTAT already has a military track record, but broad standardized procurement across the conventional force had not happened before this award. - The APFIT program is designed to move proven technologies into production and wider fielding. - The award signals continued Pentagon interest in trauma tools that can be manufactured in the U.S. and deployed more widely. - RevMedx’s long relationship with Navy, Army, and Special Operations partners appears to have helped move the technology from development into procurement support.

What's next: - RevMedx will scale production to meet military demand. - The company will work to supply XSTAT devices more broadly across the services. - The APFIT-backed expansion is expected to support continued use of XSTAT in military trauma care and further transition of the technology into the force.

The bottom line: - The $11.4 million award gives RevMedx a path to turn a niche battlefield bleeding-control device into a higher-volume military product.